Microcap Ledger DiaMedica Therapeutics Inc. $DMAC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Minneapolis, MN
- Fiscal year end
- December 31
- Shares outstanding
- 53,925,697 [10-Q 2026-08-10]
What the company doesAI summary of filing
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 protein, for the treatment of acute ischemic stroke and preeclampsia/fetal growth restriction. The company is advancing DM199 through clinical trials, including a Phase 2 investigator-sponsored trial in preeclampsia and a Phase 2/3 adaptive design trial (ReMEDy2) in acute ischemic stroke, with interim results from the preeclampsia study released in July 2025 showing the drug appeared safe and well-tolerated with blood pressure reductions. The company is pre-revenue and plans to develop a second candidate, DM300, for severe acute pancreatitis. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$20.18M | −$17.20M | $5.13M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | — | −$32.77M | −$29.06M | $15.65M | [10-K 2026-03-30] |
| FY ended Dec 2024 | — | −$24.44M | −$22.08M | $3.02M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$8.60M
- Cash runway Estimate
- ~1.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 42,760,582 | [10-Q 2024-11-13] |
| 2025-03-14 | 42,855,660 | [10-K 2025-03-17] |
| 2025-05-09 | 42,883,465 | [10-Q 2025-05-13] |
| 2025-08-08 | 51,688,913 | [10-Q 2025-08-12] |
| 2025-11-10 | 52,077,439 | [10-Q 2025-11-12] |
| 2026-03-27 | 53,882,506 | [10-K 2026-03-30] |
| 2026-05-04 | 53,883,345 | [10-Q 2026-05-06] |
| 2026-08-03 | 53,925,697 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2025-08-12; declared effective 2025-08-22 [S-3 2025-08-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-10 | Pauls Dietrich John | grant | 60,200 | — | [4 2026-08-12] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-05-21 | 8-K | Shareholder vote results |
| 2026-05-06 | 10-Q | Quarterly report |
| 2026-05-06 | 8-K | Results of operations |
| 2026-04-01 | DEF 14A | Proxy statement |
| 2026-03-31 | 8-K | Results of operations |
| 2026-03-30 | 10-K | Annual report |
| 2026-02-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-06 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-01-05 | 8-K | Other events |
Alerts for $DMAC
Email me when DiaMedica Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.